These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 29027522)

  • 21. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease.
    Banati RB; Daniel SE; Blunt SB
    Mov Disord; 1998 Mar; 13(2):221-7. PubMed ID: 9539333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.
    Grünblatt E; Ruder J; Monoranu CM; Riederer P; Youdim MB; Mandel SA
    Neurotox Res; 2018 Apr; 33(3):560-568. PubMed ID: 29218503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
    Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
    Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of non-phosphorylated neurofilament immunoreactivity, with preservation of tyrosine hydroxylase, in surviving substantia nigra neurons in Parkinson's disease.
    Gai WP; Vickers JC; Blumbergs PC; Blessing WW
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1039-46. PubMed ID: 7916375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neuromythology of Parkinson's Disease.
    Calne DB; Mizuno Y
    Parkinsonism Relat Disord; 2004 Jul; 10(5):319-22. PubMed ID: 15196512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationships between Lewy bodies and pale bodies in Parkinson's disease.
    Dale GE; Probst A; Luthert P; Martin J; Anderton BH; Leigh PN
    Acta Neuropathol; 1992; 83(5):525-9. PubMed ID: 1320323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Centenary of Tretiakoff's thesis on the morphology of Parkinson's disease, evolved on the grounds of encephalitis lethargica pathology.
    Holdorff B
    J Hist Neurosci; 2019; 28(4):387-398. PubMed ID: 31226240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease.
    Ofori E; Pasternak O; Planetta PJ; Li H; Burciu RG; Snyder AF; Lai S; Okun MS; Vaillancourt DE
    Brain; 2015 Aug; 138(Pt 8):2322-31. PubMed ID: 25981960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative morphochemical characterization of the neurons in substantia nigra of rat brain and its volume reconstruction.
    Khudoerkov RM; Voronkov DN; Dikalova YV
    Bull Exp Biol Med; 2014 Apr; 156(6):861-4. PubMed ID: 24824717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease.
    Kordower JH; Chu Y; Hauser RA; Freeman TB; Olanow CW
    Nat Med; 2008 May; 14(5):504-6. PubMed ID: 18391962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ageing and Parkinson's disease: substantia nigra regional selectivity.
    Fearnley JM; Lees AJ
    Brain; 1991 Oct; 114 ( Pt 5)():2283-301. PubMed ID: 1933245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group.
    Jenner P; Dexter DT; Sian J; Schapira AH; Marsden CD
    Ann Neurol; 1992; 32 Suppl():S82-7. PubMed ID: 1510385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease.
    Mirza B; Hadberg H; Thomsen P; Moos T
    Neuroscience; 2000; 95(2):425-32. PubMed ID: 10658622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease.
    Schipper HM; Liberman A; Stopa EG
    Exp Neurol; 1998 Mar; 150(1):60-8. PubMed ID: 9514830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.
    Kraemmer J; Kovacs GG; Perju-Dumbrava L; Pirker S; Traub-Weidinger T; Pirker W
    Mov Disord; 2014 Dec; 29(14):1767-73. PubMed ID: 25048738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A-56-year-old woman with parkinsonism, whose mother had Parkinson's disease].
    Shimo Y; Takanashi M; Ohta S; Terashima K; Mori H; Shirai T; Miwa H; Mizuno Y
    No To Shinkei; 2001 May; 53(5):495-505. PubMed ID: 11428377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
    Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.